Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancer cases and is a subtype of breast cancer characterized by the lack of oestrogen receptor (ER), progesterone receptor (PR) and ErbB-2/human epidermal growth factor receptor 2 (HER-2) expression2. Here, ERBB2 is linked to triple-negative breast carcinoma.